Keywords: Angiotech, Athersys, Cardiovascular cell therapy progra, MultiStem, Aspire share buy

Angiotech opts out of cardiovascular cell therapy program with Athersys

Article | 15 November 2011

Print This

Regenerative medicines firm Athersys (Nasdaq: ATHX) says that Canada’s Angiotech Pharmaceuticals (TSX: ANP) has pulled out of its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in